Abstract
2040 Background: It is controversial whether concurrent chemoradiotherapy (CRT) with temozolomide is feasible and beneficial in elderly patients with glioblastoma (GBM). Methods: Retrospective analysis of 76 elderly GBM patients (≥ 65 years) treated with concurrent CRT with temozolomide. Factors influencing prognosis and feasibility of CRT were investigated. Results: Median overall survival (mOS) was 11.3 months. Univariate analysis showed a significant difference in mOS for cumulative dose of concurrent temozolomide (optimal cutoff, 2655 mg/m²; 13.9 months for > 2655 mg/m² v 4.9 months for ≤ 2655 mg/m²; P = .0103). Significant independent prognostic parameters in multivariate analysis were: a cumulative dose of concurrent temozolomide > 2655 mg/m² (hazard ratio [HR], 0.41; P = .008), thrombocytopenia grade III/IV (HR, 3.05; P = .034), and biopsy only (HR, 2.10; P = .022). Hematotoxicity was the most common cause of treatment interruption or discontinuation in patients with an insufficient cumulative temo...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
